Online Only Articles

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Royal Brisbane Hospital, Herston, Australia
ALWP Office, Hospital Saint Antoine, Paris, France
CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany
Medical University of Vienna, Vienna, Austria
Singapore General Hospital, Duke-NUS Medical School, Singapore
Hematology Department, ASST Sette Laghi - Ospedale di Circolo, Varese, Italy
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Novartis Pharma AG, Basel, Switzerland
Hematology Department, Hospital 12 de Octubre, CNIO, Univ Complutense, CIBERONC, Madrid, Spain
Vol. 104 No. 12 (2019): December, 2019 https://doi.org/10.3324/haematol.2018.209965